BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

942 related articles for article (PubMed ID: 33572326)

  • 1. The Role of mTOR Signaling as a Therapeutic Target in Cancer.
    Popova NV; Jücker M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML.
    Herschbein L; Liesveld JL
    Blood Rev; 2018 May; 32(3):235-248. PubMed ID: 29276026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting PI3K in cancer: mechanisms and advances in clinical trials.
    Yang J; Nie J; Ma X; Wei Y; Peng Y; Wei X
    Mol Cancer; 2019 Feb; 18(1):26. PubMed ID: 30782187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
    Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
    Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Streptomyces sp metabolite(s) promotes Bax mediated intrinsic apoptosis and autophagy involving inhibition of mTOR pathway in cervical cancer cell lines.
    Dan VM; Muralikrishnan B; Sanawar R; J S V; Burkul BB; Srinivas KP; Lekshmi A; Pradeep NS; Dastager SG; Santhakumari B; Santhoshkumar TR; Kumar RA; Pillai MR
    Sci Rep; 2018 Feb; 8(1):2810. PubMed ID: 29434241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
    Alzahrani AS
    Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies.
    Qazi AK; Hussain A; Hamid A; Qurishi Y; Majeed R; Ahmad M; Najar RA; Bhat JA; Singh SK; Zargar MA; Ali S; Saxena AK
    Anticancer Agents Med Chem; 2013 Dec; 13(10):1552-64. PubMed ID: 23438828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
    Mabuchi S; Kuroda H; Takahashi R; Sasano T
    Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer.
    Pavlidou A; Vlahos NF
    ScientificWorldJournal; 2014; 2014():709736. PubMed ID: 24526917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.
    Wu X; Yu J; Yan J; Dai J; Si L; Chi Z; Sheng X; Cui C; Ma M; Tang H; Xu T; Yu H; Kong Y; Guo J
    Cancer Biol Ther; 2018 Jul; 19(7):584-589. PubMed ID: 29708815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
    Ediriweera MK; Tennekoon KH; Samarakoon SR
    Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J
    Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of Hypoxia-Inducible Factor 1α (HIF-1α) Promotes Autophagy and Inhibits Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Ovarian Cancer Cells.
    Huang J; Gao L; Li B; Liu C; Hong S; Min J; Hong L
    Med Sci Monit; 2019 Jun; 25():4250-4263. PubMed ID: 31175269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.
    Li H; Zeng J; Shen K
    Arch Gynecol Obstet; 2014 Dec; 290(6):1067-78. PubMed ID: 25086744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.
    Li X; Wu C; Chen N; Gu H; Yen A; Cao L; Wang E; Wang L
    Oncotarget; 2016 May; 7(22):33440-50. PubMed ID: 26967052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR: Role in cancer, metastasis and drug resistance.
    Murugan AK
    Semin Cancer Biol; 2019 Dec; 59():92-111. PubMed ID: 31408724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.
    Willems L; Tamburini J; Chapuis N; Lacombe C; Mayeux P; Bouscary D
    Curr Oncol Rep; 2012 Apr; 14(2):129-38. PubMed ID: 22350330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.